Aegerion Pharmaceuticals announced the issuance by the European Patent Office for a method of treating hyperlipidemia or hypercholesterolemia, including severe hypercholesterolemia, using step-wise, increasing doses of lomitapide. Aegerion's New Drug Application for lomitapide is under review by the U.S. FDA and its Marketing Authorization Application for lomitapide is under review by the European Medicines Agency. Aegerion is seeking approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with homozygous familial hypercholesterolemia.
- Pharmaceuticals & Drug Trials
- European Patent Office
- European Medicines Agency